Skip to content Skip to navigation

Detection of hepatic malignancies using Mn-DPDP (manganese dipyridoxal diphosphate) hepatobiliary MRI contrast agent

Publication Type:

Journal Article


Magn Reson Imaging, Volume 8, Number 3, p.267-76 (1990)

Accession Number:



Animal, Carcinoma/*diagnosis/pathology, Comparative Study, Drug Evaluation, Preclinical, Edetic Acid/diagnostic use, Image Enhancement/*methods, Liver Neoplasms, Experimental/*diagnosis/pathology, Magnetic Resonance Imaging/*methods, Pyridoxal Phosphate/*analogs & derivatives/diagnostic use, Rabbits, Support, Non-U.S. Gov't, Time Factors


A new hepatobiliary contrast agent (Mn-DPDP) was used in the detection of liver metastases in six rabbits with seven hepatic V2 carcinomas. This contrast agent is derived from pyridoxyl-5-phosphate which is biomimetically designed to be secreted by the hepatocyte. After Mn-DPDP administration, a 105% increase in liver signal to noise was obtained using a 200/20 (TR/TE) pulsing sequence, and a 62% decrease in intensity was observed using a 1200/60 pulsing sequence. Liver V2 carcinoma contrast enhancement increased 427% using the 200/20 pulsing sequence and 176% using the 1200/60 pulsing sequence. Four of seven V2 carcinomas were not detectable prior to the administration of Mn-DPDP (50 mumol/kg). Two neoplasms were only detectable in retrospect (after Mn-DPDP) on the 1200/60 sequence. The smallest neoplasms detected in this study were 1-4 mm. Mn-DPDP appears to be a promising MRI contrast agent.